Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: A total of 173 patients (7.1%) had GADA, of whom 11 (0.5%) and 5 (0.2%) were also positive for IA-2A and ZnT8A, respectively. At baseline, 44% of GADA-positive patients were not on insulin. Fewer autoantibody-positive than autoantibody-negative patients had metabolic syndrome (64 vs. 80%), and more were on insulin (56 vs. 17%) (P < 0.0001 for each) without lower HbA1c (69 mmol/mol [8.5%] vs. 62 mmol/mol [7.8%]). The frequency of microvascular and macrovascular events was similar in both cohorts, independent of atorvastatin. CONCLUSIONS:
|
Authors | Mohammed Iqbal Hawa, Ana Paula Buchan, Thomas Ola, Chuan Chuan Wun, David A DeMicco, Weihang Bao, D John Betteridge, Paul N Durrington, John H Fuller, H Andrew W Neil, Helen Colhoun, Richard David Leslie, Graham A Hitman |
Journal | Diabetes care
(Diabetes Care)
Vol. 37
Issue 6
Pg. 1643-9
(Jun 2014)
ISSN: 1935-5548 [Electronic] United States |
PMID | 24722498
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 by the American Diabetes Association. |
Chemical References |
- Anticholesteremic Agents
- Autoantibodies
- Heptanoic Acids
- Hypoglycemic Agents
- Insulin
- Pyrroles
- Atorvastatin
- Glutamate Decarboxylase
- glutamate decarboxylase 1
|
Topics |
- Adult
- Age of Onset
- Aged
- Anticholesteremic Agents
(therapeutic use)
- Atorvastatin
- Autoantibodies
(blood)
- Diabetes Mellitus, Type 1
(diagnosis, drug therapy, immunology)
- Diabetes Mellitus, Type 2
(diagnosis, drug therapy, immunology)
- Double-Blind Method
- Female
- Germany
(epidemiology)
- Glucose Intolerance
- Glutamate Decarboxylase
(immunology)
- Heptanoic Acids
(therapeutic use)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(therapeutic use)
- Male
- Metabolic Syndrome
(diagnosis, drug therapy)
- Middle Aged
- Phenotype
- Prevalence
- Prospective Studies
- Pyrroles
(therapeutic use)
- Risk Factors
|